Tumor Regression and Cure Depends on Sustained Th1 Responses. [electronic resource]
Producer: 20191001Description: 369-378 p. digitalISSN:- 1537-4513
- Animals
- Antibodies, Monoclonal -- therapeutic use
- Antigens, CD19 -- immunology
- Antineoplastic Agents, Immunological -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- CTLA-4 Antigen -- antagonists & inhibitors
- Cell Line, Tumor
- Cisplatin -- therapeutic use
- Disease Models, Animal
- Female
- Lung Neoplasms -- drug therapy
- Mice, Inbred C3H
- Mice, Inbred C57BL
- Neoplasm Recurrence, Local
- Programmed Cell Death 1 Receptor -- antagonists & inhibitors
- Th1 Cells -- drug effects
- Th2 Cells -- drug effects
- Tumor Microenvironment -- drug effects
- Tumor Necrosis Factor Receptor Superfamily, Member 9 -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.